Pharmacy benefits manager CVS Health has warned that the new PCSK9 inhibitor class of cholesterol-lowering drugs poses an unprecedented challenge to the US healthcare system. In a blog post ...
HOFH is an inherited disease that causes dangerously high levels of low-density lipoprotein cholesterol (LDL-C ... 12 years and older with HoFH. The drug’s label was later expanded in 2023 ...
The cholesterol-lowering drug has been classed as a breakthrough therapy for homozygous familial hypercholesterolaemia (HoFH) by the FDA, which is due to deliver a decision on the marketing ...
Aug. 14, 2024 — More than a quarter of Australians over the age of 50 take cholesterol-lowering drugs to prevent heart disease and strokes, but our bodies also need cholesterol to survive.
So, an elevated LDL cholesterol level is a major risk factor for heart disease and stroke. While lowering LDL cholesterol levels with statin drugs significantly reduces cardiac risk, reducing LDL ...
Low-density lipoprotein cholesterol (LDLC), also known as ‘bad cholesterol,’ contributes to plaque buildup in the arteries and causes damage, making it a ‘silent killer’ ...